Global Ranibizumab Market 2025 by Company, Regions, Type and Application, Forecast to 2031

According to our (Global Info Research) latest study, the global Ranibizumab market size was valued at US$ 3168 million in 2024 and is forecast to a readjusted size of USD 1568 million by 2031 with a CAGR of -9.7% during review period.

Ranibizumab, sold under the brand name Lucentis among others, is a monoclonal antibody fragment (Fab) created from the same parent mouse antibody as bevacizumab.

The ranibizumab market is primarily driven by the increasing prevalence of eye diseases such as age-related macular degeneration (AMD), diabetic retinopathy, and macular edema. As the global population ages and diabetes rates rise, the demand for effective treatments like ranibizumab continues to grow. Ranibizumab, an anti-VEGF (vascular endothelial growth factor) therapy, has proven highly effective in reducing vision loss and improving patient outcomes. Additionally, advancements in drug delivery methods, along with expanding healthcare access in emerging markets, are supporting the growth of the ranibizumab market.

One of the key challenges in the ranibizumab market is the high cost of the drug, which can limit patient access, particularly in developing countries or among uninsured populations. While biosimilar versions are being developed, affordability remains a concern. Additionally, there is growing competition from alternative therapies and biosimilars that offer similar efficacy at a lower price. Patient adherence to treatment regimens, which often require frequent intravitreal injections, can also be a challenge, as some patients may find the process uncomfortable or inconvenient.

Global core ranibizumab manufacturers include Roche and Novartis etc. The Top 2 companies hold a share about 98%. North America is the largest market, with a share about 51%, followed by Europe and Asia Pacific with the share about 28% and 20%.

This report is a detailed and comprehensive analysis for global Ranibizumab market. Both quantitative and qualitative analyses are presented by company, by region & country, by Type and by Application. As the market is constantly changing, this report explores the competition, supply and demand trends, as well as key factors that contribute to its changing demands across many markets. Company profiles and product examples of selected competitors, along with market share estimates of some of the selected leaders for the year 2025, are provided.

Key Features:

Global Ranibizumab market size and forecasts, in consumption value ($ Million), 2020-2031

Global Ranibizumab market size and forecasts by region and country, in consumption value ($ Million), 2020-2031

Global Ranibizumab market size and forecasts, by Type and by Application, in consumption value ($ Million), 2020-2031

Global Ranibizumab market shares of main players, in revenue ($ Million), 2020-2025

The Primary Objectives in This Report Are:

To determine the size of the total market opportunity of global and key countries

To assess the growth potential for Ranibizumab

To forecast future growth in each product and end-use market

To assess competitive factors affecting the marketplace

This report profiles key players in the global Ranibizumab market based on the following parameters - company overview, revenue, gross margin, product portfolio, geographical presence, and key developments. Key companies covered as a part of this study include Roche, Coherus, Biogen, etc.

This report also provides key insights about market drivers, restraints, opportunities, new product launches or approvals.

Market segmentation

Ranibizumab market is split by Type and by Application. For the period 2020-2031, the growth among segments provides accurate calculations and forecasts for Consumption Value by Type and by Application. This analysis can help you expand your business by targeting qualified niche markets.

Market segment by Type
Glass Vial
Prefilled Syringe

Market segment by Application
Wet AMD
Complications of Diabetes
RVO
Others

Market segment by players, this report covers
Roche
Coherus
Biogen

Market segment by regions, regional analysis covers

North America (United States, Canada and Mexico)

Europe (Germany, France, UK, Russia, Italy and Rest of Europe)

Asia-Pacific (China, Japan, South Korea, India, Southeast Asia and Rest of Asia-Pacific)

South America (Brazil, Rest of South America)

Middle East & Africa (Turkey, Saudi Arabia, UAE, Rest of Middle East & Africa)

The content of the study subjects, includes a total of 13 chapters:

Chapter 1, to describe Ranibizumab product scope, market overview, market estimation caveats and base year.

Chapter 2, to profile the top players of Ranibizumab, with revenue, gross margin, and global market share of Ranibizumab from 2020 to 2025.

Chapter 3, the Ranibizumab competitive situation, revenue, and global market share of top players are analyzed emphatically by landscape contrast.

Chapter 4 and 5, to segment the market size by Type and by Application, with consumption value and growth rate by Type, by Application, from 2020 to 2031

Chapter 6, 7, 8, 9, and 10, to break the market size data at the country level, with revenue and market share for key countries in the world, from 2020 to 2025.and Ranibizumab market forecast, by regions, by Type and by Application, with consumption value, from 2026 to 2031.

Chapter 11, market dynamics, drivers, restraints, trends, Porters Five Forces analysis.

Chapter 12, the key raw materials and key suppliers, and industry chain of Ranibizumab.

Chapter 13, to describe Ranibizumab research findings and conclusion.